FDA pharmacologic class
Poly(ADP-Ribose) Polymerase Inhibitor
4 medicines are in FDA's class of poly(adp-ribose) polymerase inhibitors: talazoparib (Talzenna), olaparib (Lynparza), niraparib (Zejula) and rucaparib camsylate (Rubraca); 1 combination product also contains one. 0 of the 5 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are poly(adp-ribose) polymerase inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Talazoparib | Talzenna | none listed | n/a | No | No current entry | 0 |
| Olaparib | Lynparza | none listed | n/a | No | No current entry | 0 |
| Niraparib | Zejula | none listed | n/a | No | No current entry | 0 |
| Rucaparib camsylate | Rubraca | none listed | n/a | No | No current entry | 0 |
| Abiraterone and niraparib | Akeega | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)